Table 2.

Current adjuvant trials in uveal melanoma.

Clinical Trials N	Tested Agent and Mechanism of Action	Phase	Status
NCT02223819	Crizotinib (c-Met inhibitor)	II	Recruiting
NCT02068586	Sunitinib (c-Kit inhibitor) vs. Valproic acid (HDAC inhibitor)	II	Recruiting
NCT00489944	Suntinib (c-Kit inhibitor) + Tamoxifen (estrogen receptor modulator) + Cisplatin (alkylating agent)	II	Unknown
NCT01983748	Dendritic cell vaccination (immunotherapy)	III	Recruiting
NCT00929019	Dendritic cell vaccination (immunotherapy)	I/II	Terminated, slow accrual
NCT02519322	Nivolumab (anti-PD1) with or without Ipilimumab (anti-CTLA4) or Relatlimab (anti-LAG3)	II	Recruiting
NCT03528408	Ipilimumab (anti-CTLA4) + Nivolumab(anti-PD1)	II	Recruiting
NCT02336763	Prophylactic External-Beam Radiation Therapy to the liver	II	Terminated, lack of accrual